- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01554254
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
August 29, 2016 updated by: Tarix Pharmaceuticals
Engraftment failure is a major obstacle to the success of cord blood transplantation in children with malignancies and inherited metabolic disorders, despite the fact that they receive relatively high doses of nucleated cells from UCB. TXA127 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (which contains the 8th amino acid conferring receptor binding to blood pressure receptors).
TXA127 has multilineage effects on hematopoietic progenitors in vitro and in vivo.
Preclinical data show that TXA127 is a novel stimulator of early multilineage hematopoietic progenitors, increases engraftment of committed hematopoietic progenitors, and induces more rapid production of platelets and neutrophils in the peripheral circulation, especially in limited cell number transplants.
Treatment with TXA127 following UCBT is expected to increase the numbers of hematopoietic progenitors and accelerate engraftment.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Pediatric Bone and Cord Blood, Duke Univ. Med. Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 20 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject, parent, or legal guardian provided written informed consent.
- Subjects must be >6 months and <21 years of age.
Subjects must have one or two available 4, 5, or 6/6 antigen matching unrelated UCB unit(s) that will deliver a cell dose between 3.0-5.0 x 107cells/kg.
- These units must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing) loci with the subject.
- If two CB units will be used, the units must be HLA-matched at 3 of 6 HLA- A, B, and DRB1 loci with each other (using same resolution of molecular typing as indicated above).
- For a single unit transplant, a minimum of 3 x 107cells/kg will be required.
- For a double unit transplant, HLA-matched units must be available such that together both units deliver a combined pre-cryopreserved nucleated cell dose of at least 4.0 x 107 cells/kg with 1 unit of at least 2.5 x 107 cells/kg and the other at least 1.5 x 107 cells/kg.
- Subjects must have histologically confirmed diagnosis of a hematologic malignancy or a laboratory confirmed inherited metabolic disease.
- Subjects who have had a prior autologous or allogeneic transplant are allowed to participate provided it has been >1 year since the transplant was completed.
- Subjects must not have active CNS disease at the time of study enrollment.
- Subjects must have a life expectancy of >4 months.
Female subjects capable of reproduction (defined as a subject who has started menses) must agree to the following:
- Use of an effective oral or IM contraceptive method during the course of the study and 2 months following the last administration of study drug.
- Female subjects capable of reproduction must have a negative pregnancy test result within 3 days prior to first study drug dose.
Subjects must have adequate function of other organ systems as measured by:
- Creatinine <2.0 mg/dL and creatinine clearance >50 mL/min.
- Hepatic transaminases (ALT/AST) <4 x ULN, bilirubin <2.0 mg/dL.
- Adequate cardiac function by echocardiogram or MUGA scan (ejection fraction or shortening fraction >80% of normal value for age).
- Pulmonary function tests demonstrating FVC and FEV1 of >60% of predicted. DLCO should be used for subjects >10 years old. Crying vital capacity of >60% may be substituted for subjects unable to complete PFTs.
Exclusion Criteria:
- Subjects with an uncontrolled infection at the time of cytoreduction.
- Subjects who are pregnant or breast feeding.
- Subjects who are known to be seropositive for HIV or HTLV-1.
- Subjects who have had an autologous or allogeneic transplant <1 year from the anticipated administration of the first dose of study drug.
- Subjects who have received treatment with an investigational agent within 30 days of anticipated administration of the first dose of study drug.
- Subjects with current alcohol use, illicit drug use or any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule.
- Subjects must not have any co-morbid condition which, in the view of the Principal Investigators, renders the subject at too high a risk from treatment complications and regimen-related morbidity/mortality.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 300mcg/kg/day for 28 days
|
300mcg/kg/day, subcutaneous injection for up to 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of TXA127 in subjects undergoing cord blood transplantation
Time Frame: Through Day 100 post transplant
|
Through Day 100 post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of TXA127 on incidence, severity and duration of aGVHD
Time Frame: Through Day 100 post transplant
|
Through Day 100 post transplant
|
|
Effect of TXA127 on incidence, severity and duration of mucositis
Time Frame: Through Day 100 post transplant
|
WHO oral toxicity score
|
Through Day 100 post transplant
|
Effect of TXA127 on neutrophil engraftment
Time Frame: Through Day 100 post transplant
|
Through Day 100 post transplant
|
|
Effect of TXA127 on platelet recovery
Time Frame: Through Day 100 post transplant
|
Through Day 100 post transplant
|
|
Effect of TXA127 on immune reconstitution
Time Frame: Through Day 100 post transplant
|
Through Day 100 post transplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kristin Page, MD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
March 12, 2012
First Submitted That Met QC Criteria
March 12, 2012
First Posted (Estimate)
March 14, 2012
Study Record Updates
Last Update Posted (Estimate)
August 31, 2016
Last Update Submitted That Met QC Criteria
August 29, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TXA127-2010-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on TXA127
-
Tarix PharmaceuticalsConstant Therapeutics LLCTerminatedMyelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Hodgkins Lymphoma | Non Hodgkins Lymphoma | Double Cord Blood TransplantUnited States
-
Tarix PharmaceuticalsWithdrawnHematologic MalignanciesUnited States
-
Tarix PharmaceuticalsConstant Therapeutics LLCTerminatedLymphoma, Non-Hodgkin | Multiple Myeloma | Hodgkin DiseaseUnited States
-
Tarix PharmaceuticalsWithdrawnHematologic MalignanciesUnited States
-
Tarix PharmaceuticalsTerminatedMyelodysplastic Syndrome (MDS)United States
-
US Biotest, Inc.Tarix PharmaceuticalsTerminatedHIV InfectionsUnited States
-
Constant Therapeutics LLCRecruitingDMD-Associated Dilated CardiomyopathyIsrael
-
Sean CollinsNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedCOVID-19 | Coronavirus Infection | SARS-CoV-2 InfectionUnited States
-
Constant Therapeutics LLCRecruiting
-
Columbia UniversityConstant Therapeutics LLCCompleted